In one paragraphArticle in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Jon OndaroDepartment of Neuroscience, Biogipuzkoa Health Research Institute (IIS Biogipuzkoa), 20014 San Sebastian, Spain.ORCID 0000-0002-2879-9497 Jose Luis Zúñiga-ElizariDepartment of Neuroscience, Biogipuzkoa Health Research Institute (IIS Biogipuzkoa), 20014 San Sebastian, Spain.ORCID 0000-0001-9766-963X Mónica ZufiríaDepartment of Neuroscience, Biogipuzkoa Health Research Institute (IIS Biogipuzkoa), 20014 San Sebastian, Spain.
Maddi Garciandia-ArcelusDepartment of Neuroscience, Biogipuzkoa Health Research Institute (IIS Biogipuzkoa), 20014 San Sebastian, Spain.
Ángela Sánchez MolledaMiaker Developments SL, Miaker Bioassays, 20014 San Sebastián, Spain.
Miren ZulaicaDepartment of Neuroscience, Biogipuzkoa Health Research Institute (IIS Biogipuzkoa), 20014 San Sebastian, Spain.
Miguel LafargaCenter for Biomedical Research of Neurodegenerative Diseases (CIBERNED), 28029 Madrid, Spain.ORCID 0000-0003-3402-1152 Javier RianchoCenter for Biomedical Research of Neurodegenerative Diseases (CIBERNED), 28029 Madrid, Spain.
Adolfo López de MunaínDepartment of Neuroscience, Biogipuzkoa Health Research Institute (IIS Biogipuzkoa), 20014 San Sebastian, Spain.ORCID 0000-0002-9509-4032 Fermin MorenoDepartment of Neuroscience, Biogipuzkoa Health Research Institute (IIS Biogipuzkoa), 20014 San Sebastian, Spain.ORCID 0000-0001-5200-3164 Francisco Javier Gil-BeaDepartment of Neuroscience, Biogipuzkoa Health Research Institute (IIS Biogipuzkoa), 20014 San Sebastian, Spain.ORCID 0000-0003-2002-5531 Gorka GerenuDepartment of Neuroscience, Biogipuzkoa Health Research Institute (IIS Biogipuzkoa), 20014 San Sebastian, Spain.ORCID 0000-0002-4981-5791 Funding
Basque Government Department of Health (Eusko Jaurlaritzako Osasun Saila) 2017222027, 2018111042, 2019222020, and 2021333050CIBERNED-Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas CB06/05/1126Department of Education of the Basque Government PRE2018_1_0095, PRE2022_1_0315, PRE2015_1_0023, and PRE2020_1_0122Diputación Foral de Gipuzkoa 2021-CIEN-000020-01EiTB Maratoia BIO17/ND/023/BDFundació La Marató 202006-32Ikerbasque Research Fellowship IKERBASQUE/RF/2023/010IKUR strategy of the Basque Government NEURODEGENPROT projectInstituto de Salud Carlos III (ISCIII) P18/01066Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union - European Regional Development Fund PI21/00153Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union through the European Regional Development Fund (ERDF) PI19/01637Juan de la Cierva-Incorporación fellowship from the Spanish Ministry of Science and Innovation IJC2019-039965-IRoche "Stop Fuga de Cerebros" program (BIO19/ROCHE/017/BD)
6 · The paper itselfAbstract
Frontotemporal dementia (FTD) is a neurodegenerative disorder predominantly affecting individuals under 65 years of age, characterized by significant behavioral and language disabilities. Despite extensive research efforts, effective treatments for FTD remain elusive. Familial cases of FTD have been linked to genetic mutations in several key genes, among these, mutations in granulin (
Indexed as
Frontotemporal DementiaLipid MetabolismMitochondriaProgranulinsFibroblastsHaploinsufficiencyHumansLysosomesMutationGRN protein, humanProgranulinsfrontotemporal dementiaFTDGRNlipid dropletslysosomemitochondrianeurodegenerationprogranulin
Identifiers
PMID41677639
PMCPMC12897215
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390